# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price ta...
Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $53 to $52.
Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leuk...
Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplanta...